日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis

对CRC原发肿瘤及其匹配的肝转移灶进行分子解剖,揭示了免疫微环境、EMT和血管生成在癌症转移中的关键作用。

Liu, Jiangang; Cho, Yong Beom; Hong, Hye Kyung; Wu, Song; Ebert, Philip J; Bray, Steven M; Wong, Swee Seong; Ting, Jason C; Calley, John N; Whittington, Catherine F; Bhagwat, Shripad V; Reinhard, Christoph; Wild, Robert; Nam, Do-Hyun; Aggarwal, Amit; Lee, Woo Yong; Peng, Sheng-Bin

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

CXCR4肽拮抗剂LY2510924联合度伐利尤单抗治疗晚期难治性实体瘤的安全性和药代动力学

O'Hara, Mark H; Messersmith, Wells; Kindler, Hedy; Zhang, Wei; Pitou, Celine; Szpurka, Anna M; Wang, Dan; Peng, Sheng-Bin; Vangerow, Burkhard; Khan, Anis A; Koneru, Mythili; Wang-Gillam, Andrea

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor

共价KRASG12C抑制剂的化学蛋白质组学表征

Wijeratne, Aruna; Xiao, Junpeng; Reutter, Christopher; Furness, Kelly W; Leon, Rebecca; Zia-Ebrahimi, Mohammad; Cavitt, Rachel N; Strelow, John M; Van Horn, Robert D; Peng, Sheng-Bin; Barda, David A; Engler, Thomas A; Chalmers, Michael J

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.

CXCR4肽拮抗剂LY2510924和单克隆抗体LY2624587可显著动员白细胞和造血干细胞

Peng Sheng-Bin, Van Horn Robert D, Yin Tinggui, Brown Robin M, Roell William C, Obungu Victor H, Ruegg Charles, Wroblewski Victor J, Raddad Eyas, Stille John R

Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data

利用基因表达谱数据鉴定细胞周期通路中与乳腺癌预后相关的基因特征

Liu, Jiangang; Campen, Andrew; Huang, Shuguang; Peng, Sheng-Bin; Ye, Xiang; Palakal, Mathew; Dunker, A Keith; Xia, Yuni; Li, Shuyu